Addex Therapeutics Ltd American Depositary Shares (ADXN)

FairStock Score: 18/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable competitive advantages, honest accounting, and a margin of safety. Addex is a three-employee Swiss biotechnology firm pursuing small-molecule treatments for neurological disorders. Its lead programs, Dipraglurant and ADX71149, are in Phase 1; there is no commercial engine, and the latest reported quarter, fiscal Q4 2025, had revenue of just $248 and a net loss of $1.8 million. That is not a business in the ordinary sense; it is a research option financed by capital markets. The balance sheet gives one small comfort: debt to equity is only 0.03. But the income statement is ugly. FairStock calculations show ROE of -122.28%, ROCE of -23.59%, trailing free cash flow of -$2.3 million, and an FCF yield of -28.8%. A Piotroski F-Score of 1/9 and an Altman Z-Score of -103.67 point to severe financial weakness. At the 2026-10-13 close of $3.01, market cap was $8.1 million, and the FairStock P/B was 0.73, so the market values it below reported book. That might tempt a Graham-style investor, but book value is being eroded by losses, and the P/E is negative at -0.35. The FairStock Score is 18/100, and the Lynch category is none because only 0 years of filed results exist where 3 are needed. Growth is not demonstrated: revenue is de minimis, and clinical success is uncertain. Without a moat, profits, or visible cash generation, this is speculation on pipeline news, not a compounding business. I would require far more evidence of financial staying power and commercial validation before calling it an investment.

In plain English: Addex Therapeutics is a very small Swiss drug company with only three employees. It is trying to develop experimental medicines for brain and nerve conditions, but it has almost no sales and is losing money. The stock price looks low compared with the value of its assets minus debts on paper, but the business itself looks weak, so the low price reflects big risks rather than a proven bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer